Press Releases

view press release archives

FDA Approves Erbitux (Cetuximab) For Treatment of Head and Neck Cancer
March 1, 2006

ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved ERBITUX (Cetuximab), an IgG1 monoclonal antibody, for use in the treatment of squamous cell carcinoma of the head and neck. more

FDA Approves First Head & Neck Cancer Treatment in 45 Years Data Shows Treatment with Erbitux Extends Survival
March 1, 2006

FDA Approves First Head & Neck Cancer Treatment in 45 Years Data Shows Treatment with Erbitux Extends Survival more